[
    [
        {
            "time": "2021-10-15",
            "original_text": "Additional Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Published in the Annals of Oncology",
            "features": {
                "keywords": [
                    "Verzenio",
                    "abemaciclib",
                    "Phase 3",
                    "monarchE",
                    "Trial Data",
                    "Annals of Oncology"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Additional Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Published in the Annals of Oncology",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-11-20",
            "original_text": "Down 76%: Is Cortexyme Stock a Bargain?",
            "features": {
                "keywords": [
                    "Cortexyme",
                    "Stock",
                    "Bargain",
                    "Down 76%"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Down 76%: Is Cortexyme Stock a Bargain?",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2022-02-10",
            "original_text": "Inventiva Plans To Start Lanifibranor Combo Study In NASH, Diabetes In 2022",
            "features": {
                "keywords": [
                    "Inventiva",
                    "Lanifibranor",
                    "Combo Study",
                    "NASH",
                    "Diabetes",
                    "2022"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Inventiva Plans To Start Lanifibranor Combo Study In NASH, Diabetes In 2022",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2022-03-05",
            "original_text": "Cortexyme's Alzheimer's Drug Fails -- 2 Lessons for Investors",
            "features": {
                "keywords": [
                    "Cortexyme",
                    "Alzheimer's",
                    "Drug",
                    "Fails",
                    "Lessons",
                    "Investors"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Cortexyme's Alzheimer's Drug Fails -- 2 Lessons for Investors",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]